

Prof. Dr. med. Amanda Tufman MD, BSc.

Personal Data

Name: Prof. Dr. med. Amanda Tufman M.D.
Date of Birth: 11.09.1980
amanda.tufman@med.uni-muenchen.de
Tel: 0049 89 4400 5 2590



Studies:

1999-2002 Bachelor of Science (BSc) Human Biology, University of Toronto
Graduated with High Distinction, 2002
2002-2006 Doctor of Medicine (MD), University of Toronto Faculty of Medicine
Graduated with Honours, 2006
Ludwig Maximilians Universität (München)
Exam 12.12.2013 ; Grade: Magna cum Laude
Topic: „IL-22 in lavage as a biomarker in patients with lung cancer“
Ludwig Maximilians Universität (München)
Date of Habilitation: 24.10.2018
Topic: „Klinische und experimentelle Untersuchungen zur individualisierten Therapie beim Lungenkarzinom“

Professional Positions

Current position	since 2024: Deputy Head of Pulmonology, Medizinische Klinik V, LMU since 2023: W2 Professorin Thorakale Onkologie, LMU since 2018: Head of the Innenstadt Campus, Department of Pneumology, Medizinische Klinik V, LMU Klinikum Co-Head of the Lung Cancer Center München (Universität München und den Asklepios Fachkliniken Gauting)
<u>06/2022</u>	primo loco W3 Professur Pneumologie Universität Ulm
<u>02/2022</u>	primo loco W2-Professur Thorakale Onkologie LMU München
<u>2021-current</u>	OnkoZert Expert for Mesothelioma
<u>2017- current</u>	OnkoZert Expert for Lung cancer
<u>09/15-03/18</u>	Senior Physician Pneumologie Innenstadt und Thorakale Onkologie der Medizinischen Klinik V am LMU Klinikum München
<u>2014-2015</u>	Staff Physician (Funktionsoberärztin) Pneumologie Innenstadt und Thorakale Onkologie der Medizinischen Klinik V am Klinikum der LMU München
<u>2010-2018</u>	Coordinator Lungentumorzentrum München an der Universität München und den Asklepios Fachkliniken Gauting
<u>2008-2014</u>	Resident Physician Pneumologie Innenstadt und Thorakale Onkologie der Medizinischen Klinik V am Klinikum der Ludwig Maximilians Universität München
<u>2006-2007</u>	Resident Physician (Assistenzärztin in Weiterbildung), Department of Anesthesia, University of Western Ontario, London, Ontario, Canada

Additional Qualification/ Professional Activities:

IASLC Staging and Prognostic Factors Group (TNM 10 Committee) 2024-present
S3 Leitlinie Lungenkarzinom 2020- present
Steering Committee ERS Assembly 11 (Thoracic Oncology): 2021- present
Mitglied der Leitgruppe Thorakale Onkologie der AIO: 2019- present
Mitglied der Leitgruppe Frauen und Familienförderung der AIO: 2019-2024
Sprecher der Leitgruppe „Young Medical Oncologists“ der AIO: 2018- 2021
Weiterbildungsberechtigung Pneumologie und Innere Medizin (BLÄK) 14.4.2018- 2022
Qualifikation Tabakentwöhnung (BLÄK) 2018
Qualifikationsprüfung Fachexperten (OnkoZert/DKG) 26.11.2016
Zertifikat Medizindidaktik der Bayerischen Universitäten 3.3.2016
Center for International Health Academic Teacher Training Program 2014 „Developing Problems for PBL“
Good Clinical Practice 2010, 2013, 2015, 2018
Grundlagenkurs Qualitätsmanagement 2.2.2010
Moderatoren-/Projektleiterschulung 08./09.6.2010
Weiterbildung zum Internen Auditor 15./16.9.2010

Recent Prizes/Awards:

- Lehrauszeichnung „Vorlesung“ WiSe 2023/2024
- FOCUS-Liste 2021-2024 Thorakale Onkologie
- Takeda Onkologie Forschungspreis 2019 (3. Platz)
- Projektförderung Curt-Bohnewald Fonds 2017 („Immunophänotypisierung des Lungenkarzinoms“)

Publications:

1. Assessing lung cancer progression and survival with infrared spectroscopy of blood serum Kepesidis KV, Stoleriu MG, Feiler N, Gigou L, Fleischmann F, Aschauer J, Eiselen S, Koch I, Reinmuth N, **Tufman A**, Behr J, Žigman M. Assessing lung cancer progression and survival with infrared spectroscopy of blood serum. *BMC Med.* 2025 Feb 21;23(1):101. doi: 10.1186/s12916-025-03924-3. PMID: 39984973; PMCID: PMC11846347.
2. Propensity score matched comparison of lymph node upstaging in early-stage lung cancer: open versus minimally invasive surgery with standardized lymphadenectomy Zimmermann J, Walter J, Pfeiffer V, Kovács J, Yavuz G, Schön J, Stoleriu MG, Ketscher C, Reinmuth N, Hatz RA, **Tufman A**, Schneider CP. Propensity score matched comparison of lymph node upstaging in early-stage lung cancer: open versus minimally invasive surgery with standardized lymphadenectomy. *J Cardiothorac Surg.* 2025 Jan 27;20(1):96. doi: 10.1186/s13019-025-03346-5. PMID: 39865313; PMCID: PMC11770911.
3. Replication study of PD-L1 status prediction in NSCLC using PET/CT radiomics Stüber AT, Heimer MM, Ta J, Fabritius MP, Hoppe BF, Sheikh G, Brendel M, Unterrainer L, Jurmeister P, **Tufman A**, Ricke J, Cyran CC, Ingrisich M. Replication study of PD-L1 status prediction in NSCLC using PET/CT radiomics. *Eur J Radiol.* 2025 Feb;183:111825. doi: 10.1016/j.ejrad.2024.111825. Epub 2024 Nov 17. PMID: 39657546.
4. [Neoadjuvant therapy for resectable non-small cell lung cancer] Welcker K, Jonigk D, Kropf-Santhen C, **Tufman A**, Draube A, Stenzinger A, Zaatar M, Thomas M. Neoadjuvante Therapie des resektablen, nicht-kleinzelligen Lungenkarzinoms [Neoadjuvant therapy for resectable non-small cell lung cancer]. *Pneumologie.* 2025 Jan;79(1):16-24. German. doi: 10.1055/a-2465-4830. Epub 2024 Dec 6. PMID: 39642922; PMCID: PMC11753866.
5. Safety of brigatinib following alectinib-induced-pneumonitis: Case report Resuli B, Galarza H, Elsner L, Kauffmann-Guerrero D, Behr J, **Tufman A**. Safety of brigatinib following alectinib-induced-pneumonitis: Case report. *Respir Med Case Rep.* 2024 Dec 27;53:102160. doi: 10.1016/j.rmcr.2024.102160. PMID: 39834688; PMCID: PMC11743586.
6. Walter J, Kauffmann-Guerrero D, Muley T, Reck M, Fuge J, Günther A, Majeed RW, Savai R, Koch I, Dinkel J, Schneider C, Senghas K, Kobinger S, Manapov F, Thomas M, Kahnert K, Winter H, Behr J, Tammemägi M, **Tufman A**. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients. *Cancer Med.* 2023 Jan 27. doi: 10.1002/cam4.5638. Online ahead of print. PMID: 36707972
7. **Tufman A**, Redmond K, Giannopoulou A, Gonzalez-McQuire S, Varriale P, Geltenbort-Rost L, Öhrling K, Scheffler M. Tufman A, et al. Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey. *Lung Cancer.* 2022 Apr 22;168:59-66. doi: 10.1016/j.lungcan.2022.04.008. Online ahead of print.
8. Sellmer L, Kovács J, Neumann J, Walter J, Kauffmann-Guerrero D, Syunyaeva Z, Fertmann J, Schneider C, Zimmermann J, Behr J, **Tufman A**. Lymphocytes and sinus histiocytosis in tumor and matched lymph nodes as predictors of survival in non-small-cell lung cancer. *Future Oncol.* 2022 Jan 13.
9. Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, **Tufman A**, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. *Cancer Immunol Immunoth.* 2021 Jun 14. doi: 10.1007/s00262-021-02981-w.
10. **Tufman A**, Neumann J, Manapov F, Sellmer L, Jung A, Kauffmann-Guerrero D, Kahnert K, Mertsch P, Borgmeier A, Semrau S, Rittmeyer A, Ulm B, Ulm K, Flentje M, Fietkau R, Huber RM. Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). *Lung Cancer.* 2021 Oct;160:17-27.